ChemoFx Assay diagnostic data
Additional data from a blinded, 9-year observational study in 262 patients with recurrent ovarian cancer showed that patients treated with a chemotherapeutic agent identified to be responsive by Precision Therapeutics' ChemoFx Assay had a significant 65% improvement in median OS vs. patients treated with drugs classified as intermediate or resistant by ChemoFx (37.5 vs. 23.9 months, p=0.01). Additionally, patients treated with a responsive drug as determined by ChemoFx had a significant improvement in PFS vs. patients treated with intermediate or resistant drugs as determined by ChemoFx (8.8 vs. 5.9 months, p=0.009). Patients' cancer cells were tested with ChemoFx to assess tumor response to 15 clinically equivalent chemotherapy options recommended for persistent or recurrent ovarian cancer by the National Comprehensive Cancer Network (NCCN). Data were published in Gynecologic Oncology. ...